Nizam Baba Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.50 M
- Paid Up Capital ₹ 2.50 M
- Company Age 2 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.86 Cr
About Nizam Baba Pharmaceuticals
Nizam Baba Pharmaceuticals Private Limited (NBPPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 May 2022 (Two years and nine months 10 days old ). Its registered office is in North 24 Parganas, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹2.86 Cr.
Subrata Adhikary and Somasree Adhikary serve as directors at the Company.
Company Details
-
Location
North 24 Parganas, West Bengal, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24230WB2022PTC253690
-
Company No.
253690
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 May 2022
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Nizam Baba Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subrata Adhikary
|
Director | 09-May-2022 | Current |
|
Somasree Adhikary
|
Director | 09-May-2022 | Current |
Financial Performance of Nizam Baba Pharmaceuticals.
Nizam Baba Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nizam Baba Pharmaceuticals?
Unlock access to Nizam Baba Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Nizam Baba Real Estate Private LimitedSubrata Adhikary and Somasree Adhikary are mutual person
Charges (Loans)
₹28.60 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 2.86 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Nov 2023 | State Bank Of India | ₹1.17 Cr | Open |
| 11 Nov 2022 | State Bank Of India | ₹1.69 Cr | Open |
How Many Employees Work at Nizam Baba Pharmaceuticals?
Nizam Baba Pharmaceuticals has a workforce of 7 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nizam Baba Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nizam Baba Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.